Hepion pharmaceuticals data safety monitoring board recommends continuation with final dose cohort in phase 2a 'ambition' clinical trial for treatment of advanced nash

- dsmb review after completion of the first dose cohort affirmed no safety or tolerability concerns with crv431 in nash patients - - dsmb recommended the ambition study continue with final dosing cohort - - final cohort expected to be completed in early 2021 - edison, nj / accesswire /  december 29, 2020 / hepion pharmaceuticals, inc. (nasdaq:hepa, "hepion"), a clinical stage biopharmaceutical company focused on artificial intelligence ("ai")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("nash") and liver disease, today announced that an independent data safety monitoring board ("dsmb") has approved the continuation of the company's phase 2a 'ambition' clinical trial. two interim analyses were performed by a dsmb to evaluate the safety and tolerability of the 75 mg crv431 dose cohort in nash patients.
HEPA Ratings Summary
HEPA Quant Ranking